{"filings":[{"id":918280,"accession_number":"0001459839-26-000059","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2026-06-08T20:09:45+00:00","items":["1.01","2.03","5.07","9.01"],"status":"ready","headline":"SI-BONE extends HQ lease through Aug 2026; annual meeting passes all proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lease term extended one month to Aug 31, 2026 with option for Sept 2026; base rent $43,696/month.","Shareholders reelected directors Dunn and Freund, ratified PwC as auditor, and approved say-on-pay.","All proposals passed with strong support; 88% of outstanding shares voted (38.9M of 44.2M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13122,"accession_number":"0001459839-26-000054","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2026-05-11T20:11:38+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q1 revenue $52.6M (+11%), net loss improves 33.8%; raises FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $52.6M (+11.2% YoY); US revenue $49.3M (+10.0%), international $3.3M (+33.9%).","Net loss $4.3M (-33.8% YoY, -$0.10 diluted EPS); adjusted EBITDA $2.5M (vs $0.5M, >440% improvement).","Gross margin stable at 79.8%; operating loss improved 31.9% to $5.1M.","Raised FY2026 revenue guidance to $230-233M (prior $228.5-232.5M); gross margin ~79% (prior ~78%).","Operational: over 1,650 active US physicians (+17%); CMS proposes new MS-DRG for complex spinal fusion with iFuse Bedrock Granite."],"consensus_eps_estimate":-0.1928,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":52588000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104212,"accession_number":"0001459839-26-000022","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","2.02","5.02","9.01"],"status":"ready","headline":"SI-BONE reports record Q4 2025 revenue of $56.3M (+15% YoY), positive adjusted EBITDA, and issues 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 worldwide revenue $56.3M, up 15% YoY; FY2025 revenue $200.9M, up 20.2% YoY.","Q4 net loss improved 63.3% to $1.6M ($0.04/diluted share); positive adjusted EBITDA $5.1M (vs $1.9M).","FY2025 net loss $18.9M vs $30.9M; positive adjusted EBITDA $8.9M (vs –$5.1M).","2026 revenue guidance $228.5M–$232.5M (~14%–16% YoY growth); expects increased adjusted EBITDA.","CFO Anshul Maheshwari appointed additional role as COO effective Feb 22, 2026."],"consensus_eps_estimate":-0.1285,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":200925000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104211,"accession_number":"0001459839-26-000010","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"SI-BONE reports preliminary FY2025 revenue ~$200.8M, up ~20% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide FY2025 revenue $200.8-$200.9M, ~20% growth; Q4 revenue $56.2-$56.3M, ~15% growth.","U.S. revenue Q4 $53.3-$53.4M (+14%); FY2025 $190.9-$191.0M (+21%).","Active U.S. physicians ~1,640, up 250 (~18% increase) from prior year.","Cash and equivalents ~$147.7M; net cash generation of ~$2.0M in Q4.","Results preliminary and subject to audit; full Q4/FY earnings call expected late Feb 2026."],"consensus_eps_estimate":-0.1285,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":200925000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120504,"accession_number":"0001459839-25-000094","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"SI-BONE Q3 revenue $48.7M (+20.6% YoY), raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $4.6M ($0.11/share) from $6.6M ($0.16) a year ago.","U.S. revenue $46.4M (+21.2% YoY); gross margin 79.8% (+75 bps); operating cash flow positive $2.3M.","FY2025 revenue guidance raised to $198M-$200M (from $195M-$198M), implying ~18-20% growth.","Adjusted EBITDA positive $2.3M vs loss $0.2M; cash and equivalents $145.7M.","Director Daniel Wolf resigned; Thomas West appointed to Audit Committee; Wolf to consult 12 months, 8,675 RSUs accelerated."],"consensus_eps_estimate":-0.1694,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":144576000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137068,"accession_number":"0001459839-25-000073","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"SI-BONE Q2 revenue up 21.7% to $48.6M; raises FY guidance; announces CCO succession","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $48.6M (+21.7% YoY); US revenue $46.4M (+22.8% YoY).","Net loss improved to $6.2M ($0.14 loss per share); positive Adj EBITDA $1.0M.","Cash flow breakeven; cash $145.5M; net cash generated $1.1M in Q2.","FY2025 guidance raised: revenue $195M-$198M (prev $193.5M-$197.5M); gross margin 78.5%-79.0%.","President Tony Recupero to retire Feb 15, 2026; Nikolas Kerr appointed CCO effective Feb 16, 2026."],"consensus_eps_estimate":-0.1877,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":95920000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154351,"accession_number":"0001459839-25-000066","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"SI-BONE shareholders elect three directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Timothy E. Davis Jr. (35.2M for), Laura A. Francis (35.5M for), Jeryl L. Hilleman (27.6M for, 8.6M withheld).","Ratification of PricewaterhouseCoopers as FY2025 auditor passed: 37.5M for, 138K against, 5.6K abstain.","Advisory vote on executive compensation approved: 35.6M for, 616K against, 3.6K abstain.","Meeting turnout: 37.7M shares voted, representing ~89% of 42.5M outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154350,"accession_number":"0001459839-25-000059","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q1 revenue up 25% to $47.3M, posts positive adjusted EBITDA, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $47.3M, up 24.9% YoY; U.S. revenue $44.8M, up 26.6%.","Gross margin 79.7% vs 78.9% a year ago; net loss improved 40% to $6.5M ($0.15/share).","Adjusted EBITDA positive $0.5M vs loss of $4.0M in Q1 2024; cash $144.4M, net cash usage down 31.7%.","FY2025 revenue guidance raised to $193.5M-$197.5M (prior $193.5M-$195.5M); expects positive adjusted EBITDA for full year.","Added 300 active U.S. physicians in Q1; CMS proposed NTAP for iFuse TORQ TNT up to $3,960/ procedure."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":47290000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172935,"accession_number":"0001459839-25-000028","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q4 2024 revenue $49M (+26% YoY); positive adjusted EBITDA; 2025 revenue guidance ~$194M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $49.0M, up 26% YoY; U.S. revenue $46.9M (+28%); gross margin ~79%.","Net loss improved ~59% to $4.5M ($0.11/diluted share) from $11.0M loss in Q4 2023.","Q4 adjusted EBITDA positive $1.9M, a ~139% improvement from -$4.8M prior year.","FY2024 revenue $167.2M (+20% YoY); net loss $30.9M, improved ~29% from $43.3M.","FY2025 revenue guidance $193.5-$195.5M (~16-17% growth); expects positive adjusted EBITDA for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":167178000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172934,"accession_number":"0001459839-25-000005","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE preliminary Q4 revenue ~$48.8-49.0M (+26% YoY); turns adjusted EBITDA profitable","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 worldwide revenue ~$48.8-49.0M (+26% YoY); US revenue ~$46.7-46.9M (+28%).","Full year 2024 worldwide revenue ~$167.0-167.1M (+20%) and US revenue ~$158.2-158.4M (+21%).","Achieved adjusted EBITDA profitability in Q4 2024; cash & securities ~$150M at quarter end.","Active US physicians rose to ~1,390 (+23% YoY).","Results are preliminary and subject to adjustment; full earnings call expected late Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":167178000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189946,"accession_number":"0001459839-24-000075","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE reports Q3 revenue $40.3M (+19% YoY); expects positive Adjusted EBITDA in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $40.3M (+19% YoY); U.S. revenue $38.3M (+18% YoY).","Net loss improved 34% to $6.6M; Adjusted EBITDA loss narrowed 94% to $0.2M.","Over 1,200 active U.S. physicians (+15%); commercialized iFuse TORQ TNT for pelvic fractures.","Updated FY2024 revenue guidance to $165-166M (prev $165-167M); expects Adj EBITDA positive in Q4.","Refinanced $36M term loan, lowered borrowing cost, extended maturity to 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":118176000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206456,"accession_number":"0001459839-24-000061","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"SI-BONE Q2 revenue $40M (+20% YoY); raises 2024 guidance to $165-167M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.0M, up 20% YoY; U.S. revenue $37.8M (+21%). Net loss $8.9M ($0.22 loss per share) improved 20%.","Adjusted EBITDA loss $2.7M, improved 43% YoY; expects positive adjusted EBITDA in Q4 2024.","Raises 2024 revenue guidance to $165M-$167M (previous $164M-$166M), implying ~19-20% growth.","Elected Daniel Wolf to Board of Directors effective Aug 5, 2024; he is SVP Chief Strategy & M&A at Baxter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":77836000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206455,"accession_number":"0001459839-24-000055","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"SI-BONE extends corporate HQ lease through July 2026, base rent $43,696/month","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Second Lease Amendment extends term 14 months to July 31, 2026 from June 1, 2025.","Base rent set at $43,696 per month ($2.00/sq ft); first three months base rent abated.","Lease covers 21,848 sq ft at 471 El Camino Real, Santa Clara, CA.","5-year extension option in original lease terminated; premises accepted AS-IS.","Security deposit of $199,570.56 continues to be held by landlord."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223611,"accession_number":"0001459839-24-000048","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"SI-BONE shareholders approve officer liability limitation; directors elected at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 89% (36.5M shares) present; all four proposals passed.","Directors Nishimura (29.7M for, 5.6M withheld) and West (35.2M for, 0.14M withheld) elected to 3-year terms.","Ratification of PwC as auditor for FY2024: 36.3M for (99.5%), 0.1M against.","Advisory say-on-pay approved: 34.7M for (98.5% of votes cast), 0.5M against.","Charter amendment to limit officer liability passed: 29.5M for, 5.7M against (approx. 84% of votes cast for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223610,"accession_number":"0001459839-24-000039","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE reports Q1 revenue $37.9M (+16% YoY); raises FY2024 guidance to $164-166M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $37.9M, up 16% YoY; U.S. revenue $35.4M, also up 16%.","Gross margin ~79%, down from ~82% due to product and procedure mix.","Net loss $10.9M ($0.27 diluted EPS) vs $11.1M ($0.32) in Q1 2023; adjusted EBITDA loss $4.0M.","FY2024 revenue guidance raised to $164-166M (18-20% growth) from $162-165M.","Surpassed 100,000 procedures; introduced smaller diameter iFuse Bedrock Granite implant."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":37867000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243034,"accession_number":"0001459839-24-000010","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE reports record Q4 revenue $38.9M (+22% YoY); FY23 revenue $138.9M (+31%); issues FY24 guidance $162-165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 worldwide revenue $38.9M (+22% YoY); US revenue $36.7M (+22%); gross margin 74% (down from 84%) due to $1.7M excess inventory reserve.","FY23 worldwide revenue $138.9M (+31% YoY); US revenue $130.6M (+32%); net loss improved 29% to $43.3M; adjusted EBITDA loss improved 48% to $17.3M.","Over 1,600 US physicians performed >15,000 procedures in 2023; active physicians grew 22% to >1,130 in Q4.","FY24 guidance: revenue $162-165M (17-19% growth); gross margin ~78%; OpEx growth ~9%; expects significant adjusted EBITDA improvement.","Cash and equivalents ~$166M; net cash usage ~$0.8M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":138886000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243033,"accession_number":"0001459839-24-000003","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"SI-BONE reports preliminary Q4 2023 revenue of $38.5-$38.7M, up ~21% YoY; FY2023 revenue ~$138.5-138.7M (+30%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 worldwide revenue $38.5-$38.7M, up ~21% YoY; US revenue $36.5-$36.6M (+22%).","FY 2023 worldwide revenue $138.5-$138.7M, up ~30% YoY; US revenue $130.5-$130.6M (+32%).","Active US surgeons ~1,130 at quarter end, up ~22% YoY.","Cash and marketable securities ~$166M as of Dec 31, 2023; net cash usage $0.8M in Q4.","Preliminary results; full Q4 earnings call expected in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":138886000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260423,"accession_number":"0001459839-23-000102","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE reports Q3 2023 record revenue of $34.0M (+29% YoY); raises FY23 guidance to $136-137M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $34.0M (+29% YoY); US revenue $32.3M (+31% YoY).","Net loss improved to $10.0M ($0.25/sh) from $14.2M ($0.41/sh) YoY.","Adjusted EBITDA loss improved 44% to -$3.9M.","Raised fiscal 2023 revenue guidance to $136M-$137M from $132M-$134M.","Over 1,040 US active surgeons (+30% YoY); 90,000 procedures worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":100027000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277714,"accession_number":"0001459839-23-000095","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"SI-BONE amends bylaws to align with SEC Universal Proxy Rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Second Amended and Restated Bylaws on September 19, 2023, effective immediately.","Amendments enhance disclosure and procedural requirements for stockholder director nominations and proposals.","Addresses SEC's Universal Proxy Rules, including use of universal proxy cards and solicitations.","Reserves white proxy card for Board's exclusive use; requires compliance with Rule 14a-19.","Also includes technical, conforming, and clarifying changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277713,"accession_number":"0001459839-23-000088","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q2 revenue $33.3M (+30% YoY); raises FY 2023 revenue guidance to $132-134M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record worldwide revenue $33.3M (+30% YoY); U.S. revenue $31.2M (+31% YoY).","Net loss improved to $11.2M ($0.30 diluted loss) from $18.5M ($0.54) in Q2 2022.","Adjusted EBITDA loss narrowed 59% to -$4.7M from -$11.5M.","FY 2023 revenue guidance raised to $132-134M (prior $128-131M), implying 24-26% growth.","Gross margin 81% vs 86% a year ago, impacted by product mix and higher depreciation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":66013000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295700,"accession_number":"0001459839-23-000083","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SI-BONE stockholders elect directors, ratify auditor, and approve executive compensation at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Dunn, Freund, and Hinckley elected with approximately 79%, 80%, and 81% of votes cast, respectively.","Ratification of PricewaterhouseCoopers as independent auditor for FY2023 passed with 30,212,416 votes for.","Advisory vote on executive compensation approved with 26,917,863 votes for (approx. 92% of votes cast excluding broker non-votes).","Total shares represented at meeting: 30,375,261, or about 86% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295699,"accession_number":"0001459839-23-000080","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SI-BONE announces public offering of 3.78M shares at $22.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,775,000 shares at $22.00 each; 3,502,247 from SI-BONE and 272,753 from selling stockholder.","Underwriters have 30-day option to purchase up to 566,250 additional shares from the company on same terms.","Offering expected to close May 9, 2023; joint book-runners include BofA, Morgan Stanley, Jefferies.","Shares listed on Nasdaq; offering made under shelf registration statement on Form S-3 filed May 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295698,"accession_number":"0001459839-23-000058","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q1 revenue $32.7M (+46% YoY), raises FY2023 guidance to $128-131M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record worldwide revenue $32.7M (+46% YoY); US revenue $30.5M (+50% YoY).","Net loss improved to $11.1M ($0.32/diluted share) from $17.4M ($0.52) a year ago.","Gross margin 82% (down from 87%) due to product mix, new implants, and higher freight/depreciation.","FY2023 revenue guidance raised to $128-131M, implying 20-23% annual growth.","Over 950 active US surgeons (+40% YoY); cash $86M, borrowings $35.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":32708000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316239,"accession_number":"0001459839-23-000014","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q4 revenue up 27% to $32M; issues 2023 guidance of $124-127M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 worldwide revenue $32.0M (+27% YoY); full year $106.4M (+18% YoY).","U.S. revenue Q4 $30.0M (+28%); active surgeons over 920 (+33% YoY).","Net loss Q4 $11.2M ($0.32/sh) vs $14.5M ($0.43) prior year; adjusted EBITDA loss improved 54% to $4.2M.","2023 guidance: revenue $124-127M (17-19% growth); gross margin ~80%; adjusted EBITDA loss to improve.","Refinanced $35M term loan with new $51M credit facility ($36M term + $15M revolver)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":106409000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316238,"accession_number":"0001459839-23-000003","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"SI-BONE reports preliminary Q4 revenue ~$31.8M (+26% YoY) and refinances debt with $51M SVB facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 preliminary revenue $31.7-31.9M, up ~26% YoY; FY 2022 revenue $106.1-106.3M, up ~18%.","U.S. Q4 revenue $29.8-29.9M (+28%); active surgeons reached record 920 (+33% YoY).","Cash & marketable securities ~$96M as of Dec 31, 2022.","Refinanced existing $35M SVB term loan with new $51M facility: $36M term loan (due 2027) plus $15M revolver (due 2025), plus $15M accordion.","Term loan interest at prime+0.5% (floor 6.75%); amortization begins July 2025; revolver based on 80% eligible receivables."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":106409000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334534,"accession_number":"0001459839-22-000042","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE posts Q3 2022 record revenue of $26.4M, up 19% YoY; guides FY22 revenue $104-105M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $26.4M (+19% YoY); U.S. revenue $24.6M (+21% YoY).","Gross margin 84% vs 89% YoY, pressured by product mix, lower ASPs, and higher freight.","Net loss $14.2M ($0.41/share) vs $15.9M ($0.48/share) in prior year.","FY2022 revenue guidance raised to $104-105M (16-17% growth); implies Q4 of $29.5-30.5M.","Over 800 U.S. active surgeons (+27% YoY); CMS finalized ~26-33% Medicare facility fee hike for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":74456000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351948,"accession_number":"0001459839-22-000035","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q2 revenue $25.6M (+15% YoY); net loss $18.5M ($0.54/share)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record worldwide revenue $25.6M, up 15% YoY; U.S. revenue $23.8M, up 18% YoY.","Gross margin 86% vs 89% YoY; operating loss $17.9M vs $13.0M.","Net loss $18.5M ($0.54 per diluted share) vs $14.0M ($0.42) in Q2 2021.","Cash $114.4M; long-term borrowings $35.1M; FY2022 revenue guidance reaffirmed at $106-108M.","FDA clearances for iFuse-TORQ pelvic fractures and iFuse Bedrock Granite; CMS NTAP up to $9,828."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":48024000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369402,"accession_number":"0001459839-22-000032","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SI-BONE shareholders elect all three director nominees at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Davis, Francis, and Hilleman elected with ~22.3M votes each; 2.6M broker non-votes.","Ratification of PwC as auditor for FY2022 approved: 30.8M for, 63k against.","Advisory approval of executive compensation passed: 27.4M for, 1.0M against.","Stockholders preferred annual advisory votes on exec compensation (27.9M for one year).","Company will hold say-on-pay votes annually for the next six years through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369401,"accession_number":"0001459839-22-000027","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q1 revenue $22.4M (+10% YoY); net loss $17.4M; reaffirms FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $22.4M, up 10% YoY; U.S. revenue $20.4M (+9%), international $2.1M (+24%.","Gross margin 87% (vs 89% in Q1 2021); operating loss $16.9M vs $11.6M a year ago.","Net loss $17.4M ($0.52 per diluted share) compared to $12.2M ($0.37 per share) in Q1 2021.","Cash and marketable securities $130.7M, long-term borrowings $35.0M as of March 31, 2022.","Reaffirmed FY2022 revenue guidance of ~$106M to $108M, representing 18%-20% growth over 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":22439000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388589,"accession_number":"0001459839-22-000012","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE reports Q4 2021 revenue $25.2M (+14% YoY); net loss $0.43/share; FY2022 guidance $106-108M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $25.2M, up 14% YoY; full-year 2021 revenue $90.2M, up 23% YoY.","Q4 net loss $14.5M ($0.43/diluted share) vs $9.0M ($0.28) in Q4 2020.","Gross margin 87% in Q4 2021 (90% in Q4 2020); full-year gross margin 88%.","Cash and marketable securities $147.0M as of Dec 31, 2021.","FY2022 revenue guidance $106M-$108M (18-20% growth); cautious on COVID impact on elective procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":90152000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388588,"accession_number":"0001459839-22-000006","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"SI-BONE preliminary Q4 revenue $24.9-25.2M (+13-14% YoY); FY2021 revenue $89.8-90.1M (+22-23%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2021 revenue $24.9-25.2M, up 13-14% YoY; U.S. revenue $23.1-23.3M (+12-13%).","Full year 2021 revenue $89.8-90.1M, up 22-23% YoY; U.S. $82.5-82.7M, international $7.3-7.4M.","Cash and marketable securities approx. $146M as of Dec 31, 2021; results are preliminary and unaudited.","CEO Laura Francis granted 63,865 time-based RSUs and up to 127,728 performance-based RSUs; CFO Anshul Maheshwari granted 41,802 RSUs and up to 27,868 PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":90152000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406520,"accession_number":"0001459839-21-000059","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE Q3 record revenue $22.3M (+9% YoY); net loss $15.9M; FY21 guidance $89-90M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 worldwide revenue $22.3M, up 9% YoY; U.S. revenue $20.4M (+8%), international $1.9M (+31%).","Gross margin improved to 89% (87% YoY); operating loss widened to $13.2M from $8.7M.","Net loss $15.9M ($0.48/sh) vs $9.5M ($0.33/sh); includes $1.8M debt extinguishment costs.","Received UnitedHealthcare exclusive iFuse coverage for SI Joint Fusion, covering ~160M U.S. lives.","FY2021 revenue guidance updated to ~$89-90M (21-23% growth); cash and securities $160.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":64922000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425519,"accession_number":"0001459839-21-000056","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"SI-BONE enters $35M SVB term loan, repays $41.7M Solar Capital facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$35M term loan from Silicon Valley Bank at greater of 5.75% or prime+2.5%; matures Aug 2025 or Aug 2026 if milestone met.","Proceeds used to repay Solar Capital term loan; total payment $41.7M ($41M principal+final fee, $0.6M prepayment fees).","Loan secured by substantially all assets except IP; includes affirmative/negative covenants and customary events of default.","Monthly principal amortization starts Sep 2023; prepayment fee 1% if within 2 years, 0% after."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425518,"accession_number":"0001459839-21-000051","cik":1459839,"company_name":"SI-BONE, Inc.","ticker":"SIBN","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SI-BONE posts record Q2 revenue of $22.2M, gets exclusive Anthem coverage","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 worldwide revenue $22.2M (+58% YoY); U.S. revenue $20.2M (+53%).","Exclusive coverage from Anthem (40M+ members) expands SI joint fusion access; also positive Centene coverage.","Gross margin 89%; guidance raised to 87-89%; FY2021 revenue guidance maintained $92-94M.","Net loss $14.0M ($0.42/sh) vs $12.5M ($0.44/sh) prior year; operating loss $13.0M.","Published 2-year clinical trial results for iFuse-3D Implant System, 95th peer-reviewed publication."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":42636000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641290609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}